REFERENCES

1. World Health Organization. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. 2012. Available at: http://globocan.iarc.fr/Pages/fact_sheets_popula- tion.aspx.

2. National Cancer Institute. Endometrial cancer treatment: phys­ician data query (PDQ). 2015. Available at: https://www.cancer. gov/types/uterine/hp/endometrial-treatment-pdq/.

3. Bokhman JV Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983;15:10-17.

4. Prat J, Gallardo A, Cuatrecasas M, Catasus L. Endometrial car­cinoma: pathology and genetics. Pathology 2007;39:72-87.

5. McCluggage WG. Uterine carcinosarcomas (malignant mixed Mullerian tumours) are metaplastic carcinomas. Int J Gynecol Cancer 2002;12:687-90.

6. Zhang Y, Liu H, Yang S, et al. Overweight, obesity and endomet­rial cancer risk: results from a systematic review and meta-ana- lysis. Int J Biol Markers 2014;29:21-29.

7. Lancaster JM, Powell CB, Chen LM, Richardson DL. Society of Gynecologic Oncology statement on risk assessment for gyneco­logic cancer predispositions. Gynecol Oncol 2015;136:3-7.

8. Morgensen J, Kjaer S, Mellemkjaer, Jensen A. Endometriosis and risks for ovarian, endometrial and breast cancers: a nationwide cohort study. Gynecol Oncol 2016;143:87-92.

9. Chandra V, Kim JJ, Benbrook DM, Dwivedi A, Rai R. Therapeutic options for management of endometrial hyperplasia. J Gynecol Oncol 2016;27:e8.

10. Dinger J, Bardenheuer, Minh T. Levonorgestrel-releasing and copper intrauterine devices and the risk of breast cancer. Contraception 2011;83:211-17.

11. Trinh XB, Tjalma WA, Makar AP, Buytaert G, Weyler J, van Dam PA. Use of the levonorgestrel-releasing intrauterine system in breast cancer patients. Fertil Steril 2008;90:17-22.

12. Backman T, Rauramo I, Jaakkola K, et al. Use of the levonor­gestrel-releasing intrauterine system and breast cancer.

13. Wong AW, Chan SS, Yeo W, Yu MY, Tam WH. Prophylactic use of levonorgestrel-releasing intrauterine system in women with breast cancer treated with tamoxifen: a randomized controlled trial. Obstet Gynecol 2013;121:943-50.

14. Colombo N, Creutzberg C, Amant F, et al. ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treat­ment and follow-up. Int J Gynecol Cancer 2016;26:2-30.

15. Schmeler KM, Lynch HT, Chen L. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 2006;354:261-69.

16. Yang Y, Liao Y, Liu X, et al. Prognostic factors of regression and relapse of complex atypical hyperplasia and well-differentiated endometrioid carcinoma with conservative treatment. Gynecol Oncol 2015;139:419-23.

17. Orbo A, Vereide A, Arnes M, Pettersen I, Straume B. Levonorgestrel-impregnated intrauterine device as treatment for endometrial hyperplasia: a national multicentre randomised trial. BJOG 2014;121:477-86.

18. Dijkhuizen F, Mol B, Brolman H, Heintz A. The accuracy of endo­metrial sampling in the diagnosis of patients with endometrial carcinoma and hyperplasia. Cancer 2000;89:1765-72.

19. Dimitraki M, Tsikouras P, Bouchlariotou S, et al. Clinical evalu­ation of women with PMB. Is it always necessary an endometrial biopsy to be performed? A review of the literature. Arch Gynecol Obstet 2011;283:261-66.

20. Wang J, Wieslander C, Hansen G, et al. Thin endometrial echo complex on ultrasound does not reliably exclude type 2 endomet­rial cancers. Gynecol Oncol 2006;101:120-25.

21. Chandavarkar U, Kuperman JM, Muderspach LI, et al. Endometrial echocomplex thickness in postmenopausal endo­metrial cancer. Gynecol Oncol 2013;131:109-12.

22. Jhang H, Chuang L, Visintainer P, Ramaswamy G. CA 125 levels in the pre-operative assessment of advanced stage uterine cancer. Am J Obstet Gynecol 2003;188:1195-97.

23. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium.

24. Takeshima N, Nishida H, Tabata T, et al. Positive peritoneal cy­tology in endometrial cancer: enhancement of other prognostic indicators. Gynecol Oncol 2001;82:470-73.

25. Shih K, Yun E, Gardner G, et al. Surgical cytoreduction in stage IV endometrioid endometrial carcinoma. Gynecol Oncol 2011;122:608-11.

26. Walker J, Piedmonte M, Spirtos N, et al. Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group Study LAP2. J Clin Oncol 2009;27:5331-36.

27. Galaal K, Bryant A, Fisher A, et al. Laparoscopy versus laparotomy for the management of early stage endometrial cancer. Cochrane Database Syst Rev 2012;9:CD006655.

28. Walker J, Piedmonte M, Spirtos N, Eisenkop S, Schlaerth J. Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group LAP2 Study. J Clin Oncol 2012;30:695-700.

29. Cardenas-Goicoechea J, Shepard A, Momeni M, et al. Survival analysis of robotic versus traditional laparoscopic surgical staging for endometrial cancer. Am J Obstet Gynecol 2014;210:160.e1-11.

30. Gitsch G, Hanzal E, Jensen D, Hacker N. Endometrial cancer in premenopausal women 45 years and younger. Obstet Gynecol 1995;85:504-508.

31. Panici P, Baisile F, Maneschi A, et al. Systematic pelvic lymphadenectomy vs no lymphadenectomy in early-stage endo­metrial cancer: randomized clinical trial. J Natl Cancer Inst 2008;100:1707-16.

32. ASTEC study group, Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK. Efficacy of systematic pelvic Fymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet 2009;373:125-36.

33. Goff B, Rice L. Assessment of depth of myometrial invasion in endometrial adenocarcinoma. Gynecol Oncol 1990;38:46-48.

34. Franchi M, Ghezzi F, Melpignano M, et al. Clinical value of intraoperative gross examination in endometrial cancer.

35. Schink J, Lurain J, Wallemark C, Chmiel J. Tumour size in endo­metrial cancer: a prognostic factor for lymph node metastasis. Obstet Gynecol 1987;70:216-19.

36. Ryan M, Stainton MC, Slaytor EK, Jaconelli C, Watts S, Mackenzie P. Aetiology and prevalence oflower limb lymphoedema following treatment for gynaecological cancer. Aust N Z J Obstet Gynaecol 2003;43:148-51.

37. Mariani A, Dowdy SC, Cliby WA, et al. Efficacy of systematic lymphadenectomy and adjuvant radiotherapy in node-positive endometrial cancer patients. Gynecol Oncol 2006;101:200-208.

38. Nomura H, Aoki D, Suzuki N, et al. Analysis of clinico-pathologic factors predicting para-aortic lymph node metastasis in endomet­rial cancer. Int J Gynecol Cancer 2006;16:799-804.

39. Abu-Rustum N, Gomez JD, Alektiar KM, et al. The incidence of isolated paraaortic nodal metastases in surgically staged endo­metrial cancer patients with negative pelvic lymph nodes. Gynecol Oncol 2009;115:236-38.

40. Ballester M, Dubernard G, Lecuru F, et al. Detection rate and diagnostic accuracy of sentinel-node biopsy in early stage endo­metrial cancer: a prospective multicenter study (SENTI-ENDO). Lancet Oncol 2011;12:469-76.

41. Creutzberg CL, van Putten WL, Koper PC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicenter randomised trial. PORTEC study group. Post operative radiation therapy in endo­metrial carcinoma. Lancet 2000;333:1404-11.

42. Nout RA, Smit VT, Putter H, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet 2010;375:816-23.

43. Blake P, Swart AM, Orton J, et al. Adjuvant external beam radio­therapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, system­atic review, and meta-analysis.

44. Creutzberg CL. GOG-99: ending the controversy regarding pelvic radiotherapy for endometrial carcinoma. Gynecol Oncol 2004;92:740-43.

45. Sutton G, Kauderer J, Carson LF, et al. Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol 2005;96:630-34.

46. Slaughter KN, Rowland M, Bhattacharya R, et al. Integration of adjuvant chemotherapy in first-line management of uterine carcinosarcoma. Gynecol Oncol 2015;137:97.

47. Galaal K, van der Heijden E, Godfrey K, et al. Adjuvant radio­therapy and/or chemotherapy after surgery for uterine carcinosarcoma. Cochrane Database Syst Rev 2013;2:CD006812.

48. Secord AA, Havrilesky LJ, Bae- Jump V, et al. The role of multi-mo­dality adjuvant chemotherapy and radiation in women with ad­vanced stage endometrial cancer. Gynecol Oncol 2007;107:285-91.

49. Fleming GF, Brunetto VL, Cella D, et al. Phase III trial of doxo­rubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 22:2159-66.

50. Randall ME, Filiaci VL, Muss H, et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 2006;24:36-44.

51. Winder A, Yu Y, Unno K, Kim J. The efficacy of an AKT inhibitor for treatment of aggressive endometrial cancer: studied in new models for cancer research. Gynecol Oncol 2014;135:392.

52. Slomovitz BM, Coleman RL. The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer. Clin Cancer Res 2012;18:5856-64.

53. Cantrell LA, Zhou C, Mendivil A, et al. Metformin is a potent in­hibitor of endometrial cancer cell proliferation—implications for a novel treatment strategy. Gynecol Oncol 2010;116:92-98.

54. Bandyopadhyay S, Arabi H, Thirabanjasak D, Quddus MR, Lawrence WD, Fehmi RA.

55. Kinkel K, Kaji Y, Yu KK, et al. Radiologic staging in patients with endometrial cancer: a meta-analysis. Radiology 1999;212:711-18.

56. Ushijima K, Yahata H, Yoshikawa H, et al. Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. J Clin Oncol 2007;25:2798-803.

57. FIGO Committee on Gynecologic Oncology. FIGO staging for uterine sarcomas. Int J Gynecol Oncol 2009;104:179.

58. Jones MW, Norris HJ. Clinicopathologic study of 28 uterine leiomyosarcomas with metastasis. IntJ Gynecol Pathol 1995;14:243-49.

59. Prat J, Mbatani NH. Uterine sarcomas. Int J Gynecol Obstet 131:S105-110.

60. Horng H, Wen K, Wang P, et al. Uterine sarcoma. Part II - uterine endometrial stromal sarcoma: the TAG systematic review. Taiwan J Obstel Gynecol 2016;55:472-79.

61. Chu M, Mor G, Lim C, et al. Low-grade endometrial stromal sar­coma: hormonal aspetcs. Gynecol Oncol 2003;90:170-76.

62. Major FJ, Blessing JA, Silverberg SG, et al. Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study. Cancer 1993;71:1702-709.

63. Bogani G, Maltese G, Ditto A, et al. Efficacy of adjuvant chemo­therapy in early stage uterine leiomyosarcoma: a systematic re­view and meta-analysis. Gynecol Oncol 2016;143:443-47.

64. Roque DR, Taylor KN, Palisoul M, et al. Gemcitabine and docetaxel compared to radiation or other chemotherapy regimens as adjuvant treatment for stages I-IV uterine leiomyosarcoma. Int J Gynecol Cancer 2016;26:505-11.

65. Taylor K, Palisoul M, Rogue DR, et al. Gemcitabine and docetaxel compared to alternative chemotherapy regimens as adjuvant treat­ment for uterine leiomyosarcoma. Gynecol Oncol 2015; 136:408.

66. Hensley ML, Miller A, O’Malley DM, et al. A randomized phase III trial of gemcitabine + docetaxel + bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma (uLMS): a Gynecologic Oncology Group study. Gynecol Oncol 2014;133 Suppl 1:3.

67. Reed NS, Mangioni C, Malmstro H, et al. Phase III ran­domised study to evaluate the role of adjuvant pelvic radio­therapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Eur J Cancer 2008;44:808-18.